Latest Regulatory Filings News

Metal Bank Limited reported a net cash outflow of $161,000 for the December 2024 quarter, maintaining $1.2 million in cash reserves supported by recent financing activities.

LiveHire’s 2Q25 report reveals a sharp rise in operating cash outflows and a dip in SaaS revenue, offset by strong growth in its North American Direct Sourcing business and a strategic capital raise amid an ongoing takeover.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

Lefroy Exploration Limited reported a modest net cash decrease in the December quarter, ending with $3.24 million in cash reserves and nearly four quarters of funding available. The company continues to invest heavily in exploration activities despite operating cash outflows.

Vulcan Energy Resources reported a robust cash position of €97 million at the end of 2024 despite significant cash outflows driven by exploration and development activities. The company’s strong liquidity is supported by unused financing facilities, positioning it well for upcoming operational demands.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.

Auric Mining Limited reports a robust cash flow quarter ending December 31, 2024, with current assets reaching approximately $10 million and ongoing cash inflows from its joint venture at Jeffreys Find Gold Mine.

Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.

Alterity Therapeutics has reported positive Phase 2 results for ATH434, showing significant slowing of Multiple System Atrophy progression and a favorable safety profile. The trial demonstrated clinical benefits alongside reductions in brain iron accumulation, a key disease driver.

Impact Minerals Limited reported its December 2024 quarterly cash flow, revealing ongoing exploration expenditures and a significant $2.87 million grant to commercialise its High Purity Alumina process at Lake Hope.

Bluechiip Limited reported a $221,000 net cash outflow for Q2 FY2025, with cash reserves dwindling to $121,000. The company has initiated a strategic review and plans a capital raise to secure its future.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.